Dara Lee Luca1, Jeffrey C Kwong2,3,4,5,6, Anna Chu2, Beate Sander2,3,7, Ryan O'Reilly7, Allison J McGeer5,8, David E Bloom9. 1. Mathematica Policy Research, Cambridge, Massachusetts. 2. Institute for Clinical Evaluative Sciences. 3. Public Health Ontario. 4. Department of Family and Community Medicine. 5. Dalla Lana School of Public Health, University of Toronto. 6. University Health Network. 7. Institute of Health Policy, Management and Evaluation, University of Toronto. 8. Sinai Health System, Toronto, Ontario, Canada. 9. Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.
Abstract
Background: In Ontario, Canada, pneumococcal conjugate vaccine (PCV) was approved for infants in 2001 and became part of the publicly funded routine immunization schedule in 2005. We assessed the population-level impact of PCV on pneumonia hospitalizations and related costs. Methods: We used the difference-in-differences approach to evaluate the impact of pneumococcal vaccination on pneumonia hospitalizations and related costs, using nonpneumonia hospitalization as the control condition. We extracted monthly hospitalization costs, stratified by age group, from population-based health administrative data between April 1992 and March 2014. The study period was divided into 5 intervals: prevaccine period, availability of 7-valent PCV (PCV7) for private purchase, public funding for PCV7, replacement of PCV7 with 10-valent PCV (PCV10), and replacement of PCV10 with 13-valent PCV (PCV13). Results: A total of 1063700 pneumonia hospitalizations were recorded during the study period. In the vaccine-eligible age group, pneumonia hospitalizations declined by 34% (95% confidence interval, 32%-37%), 38% (32%-43%), and 45% (40%-51%) and hospitalization-related costs declined by 38% (25%-51%), 39% (33%-45%), and 46% (41%-52%) after public funding for PCV7, PCV10, and PCV13, respectively. Pneumonia hospitalizations and related costs also declined substantially for PCV-ineligible older children and elderly persons (aged >65 years). Conclusions: Our results suggest that the publicly funded PCV immunization program is responsible for substantial reductions in pneumonia hospitalizations and related healthcare costs, among both young children eligible for publicly funded vaccination and other age groups not included in the publicly funded program.
Background: In Ontario, Canada, pneumococcal conjugate vaccine (PCV) was approved for infants in 2001 and became part of the publicly funded routine immunization schedule in 2005. We assessed the population-level impact of PCV on pneumonia hospitalizations and related costs. Methods: We used the difference-in-differences approach to evaluate the impact of pneumococcal vaccination on pneumonia hospitalizations and related costs, using nonpneumonia hospitalization as the control condition. We extracted monthly hospitalization costs, stratified by age group, from population-based health administrative data between April 1992 and March 2014. The study period was divided into 5 intervals: prevaccine period, availability of 7-valent PCV (PCV7) for private purchase, public funding for PCV7, replacement of PCV7 with 10-valent PCV (PCV10), and replacement of PCV10 with 13-valent PCV (PCV13). Results: A total of 1063700 pneumonia hospitalizations were recorded during the study period. In the vaccine-eligible age group, pneumonia hospitalizations declined by 34% (95% confidence interval, 32%-37%), 38% (32%-43%), and 45% (40%-51%) and hospitalization-related costs declined by 38% (25%-51%), 39% (33%-45%), and 46% (41%-52%) after public funding for PCV7, PCV10, and PCV13, respectively. Pneumonia hospitalizations and related costs also declined substantially for PCV-ineligible older children and elderly persons (aged >65 years). Conclusions: Our results suggest that the publicly funded PCV immunization program is responsible for substantial reductions in pneumonia hospitalizations and related healthcare costs, among both young children eligible for publicly funded vaccination and other age groups not included in the publicly funded program.
Authors: David N Fisman; Elias Abrutyn; Kimberly A Spaude; Alex Kim; Cheryl Kirchner; Jennifer Daley Journal: Clin Infect Dis Date: 2006-03-13 Impact factor: 9.079
Authors: Seema Jain; Derek J Williams; Sandra R Arnold; Krow Ampofo; Anna M Bramley; Carrie Reed; Chris Stockmann; Evan J Anderson; Carlos G Grijalva; Wesley H Self; Yuwei Zhu; Anami Patel; Weston Hymas; James D Chappell; Robert A Kaufman; J Herman Kan; David Dansie; Noel Lenny; David R Hillyard; Lia M Haynes; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Richard G Wunderink; Kathryn M Edwards; Andrew T Pavia; Jonathan A McCullers; Lyn Finelli Journal: N Engl J Med Date: 2015-02-26 Impact factor: 91.245
Authors: Wallis Rudnick; Zhong Liu; Altynay Shigayeva; Donald E Low; Karen Green; Agron Plevneshi; Roslyn Devlin; James Downey; Kevin Katz; Ian Kitai; Sigmund Krajden; Krystyna Ostrowska; David Richardson; Susan Richardson; Alicia Sarabia; Michael Silverman; Andrew E Simor; Gregory Tyrrell; Allison McGeer Journal: Vaccine Date: 2013-10-05 Impact factor: 3.641
Authors: Steven B Black; Henry R Shinefield; Stella Ling; John Hansen; Bruce Fireman; David Spring; Jack Noyes; Edwin Lewis; Paula Ray; Janelle Lee; Jill Hackell Journal: Pediatr Infect Dis J Date: 2002-09 Impact factor: 2.129
Authors: Carlos G Grijalva; J Pekka Nuorti; Patrick G Arbogast; Stacey W Martin; Kathryn M Edwards; Marie R Griffin Journal: Lancet Date: 2007-04-07 Impact factor: 79.321
Authors: Jeffrey C Kwong; Sujitha Ratnasingham; Michael A Campitelli; Nick Daneman; Shelley L Deeks; Douglas G Manuel; Vanessa G Allen; Ahmed M Bayoumi; Aamir Fazil; David N Fisman; Andrea S Gershon; Effie Gournis; E Jenny Heathcote; Frances B Jamieson; Prabhat Jha; Kamran M Khan; Shannon E Majowicz; Tony Mazzulli; Allison J McGeer; Matthew P Muller; Abhishek Raut; Elizabeth Rea; Robert S Remis; Rita Shahin; Alissa J Wright; Brandon Zagorski; Natasha S Crowcroft Journal: PLoS One Date: 2012-09-04 Impact factor: 3.240
Authors: Sharifa Nasreen; Jun Wang; Manish Sadarangani; Jeffrey C Kwong; Caroline Quach; Natasha S Crowcroft; Sarah E Wilson; Allison McGeer; Shaun K Morris; James D Kellner; Beate Sander; Julianne V Kus; Linda Hoang; Fawziah Marra; Shaza A Fadel Journal: BMJ Open Respir Res Date: 2022-06
Authors: Michele R Wilson; Matthew D Wasserman; Marie-Claude Breton; Francois Peloquin; Stephanie R Earnshaw; Cheryl McDade; Heather L Sings; Raymond A Farkouh Journal: Infect Dis Ther Date: 2020-04-08
Authors: Josephine Storch; Carolin Fleischmann-Struzek; Norman Rose; Thomas Lehmann; Anna Mikolajetz; Srikanth Maddela; Mathias W Pletz; Christina Forstner; Ole Wichmann; Julia Neufeind; Monique Vogel; Konrad Reinhart; Horst Christian Vollmar; Antje Freytag Journal: Eur J Health Econ Date: 2021-07-20